Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Preferred Stock Liabilities (2018 - 2019)

Revolution Medicines (RVMD) has 1 years of Preferred Stock Liabilities data on record, last reported at $305.1 million in Q4 2019.

  • For Q4 2019, Preferred Stock Liabilities changed N/A year-over-year to $305.1 million; the TTM value through Dec 2019 reached $305.1 million, changed N/A, while the annual FY2019 figure was $305.1 million, 48.77% up from the prior year.
  • Preferred Stock Liabilities reached $305.1 million in Q4 2019 per RVMD's latest filing, roughly flat from $305.1 million in the prior quarter.
  • Across five years, Preferred Stock Liabilities topped out at $305.1 million in Q3 2019 and bottomed at $205.1 million in Q1 2019.